Vanguard Group’s TFF Pharmaceuticals, Inc. Common Stock TFFP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-12,136
| Closed | -$24.4K | – | 4343 |
|
|
2024
Q3 | $24.4K | Hold |
12,136
| – | – | ﹤0.01% | 4290 |
|
|
2024
Q2 | $20.1K | Sell |
12,136
-22,607
| -65% | -$59.3K | ﹤0.01% | 4360 |
|
|
2024
Q1 | $210K | Buy |
34,743
+870
| +3% | +$5.69K | ﹤0.01% | 4173 |
|
|
2023
Q4 | $238K | Sell |
33,873
-2
| -0% | -$16 | ﹤0.01% | 4194 |
|
|
2023
Q3 | $296K | Sell |
33,875
-272
| -0.8% | -$2.55K | ﹤0.01% | 4186 |
|
|
2023
Q2 | $401K | Sell |
34,147
-231
| -0.7% | -$3.32K | ﹤0.01% | 4179 |
|
|
2023
Q1 | $589K | Hold |
34,378
| – | – | ﹤0.01% | 4078 |
|
|
2022
Q4 | $902K | Sell |
34,378
-359
| -1% | -$17K | ﹤0.01% | 3941 |
|
|
2022
Q3 | $3.53M | Hold |
34,737
| – | – | ﹤0.01% | 3504 |
|
|
2022
Q2 | $4.91M | Buy |
34,737
+138
| +0.4% | +$19.3K | ﹤0.01% | 3383 |
|
|
2022
Q1 | $5.46M | Buy |
34,599
+2,112
| +7% | +$341K | ﹤0.01% | 3484 |
|
|
2021
Q4 | $7.2M | Buy |
32,487
+685
| +2% | +$133K | ﹤0.01% | 3411 |
|
|
2021
Q3 | $6.14M | Buy |
31,802
+928
| +3% | +$197K | ﹤0.01% | 3526 |
|
|
2021
Q2 | $7.42M | Buy |
30,874
+2,998
| +11% | +$822K | ﹤0.01% | 3370 |
|
|
2021
Q1 | $9.46M | Buy |
27,876
+2,805
| +11% | +$1.14M | ﹤0.01% | 3172 |
|
|
2020
Q4 | $8.98M | Buy |
25,071
+11,890
| +90% | +$4.58M | ﹤0.01% | 3047 |
|
|
2020
Q3 | $6.09M | Buy |
13,181
+10,638
| +418% | +$3M | ﹤0.01% | 3047 |
|
|
2020
Q2 | $366K | Hold |
2,543
| – | – | ﹤0.01% | 3838 |
|
|
2020
Q1 | $244K | Buy |
2,543
+462
| +22% | +$55K | ﹤0.01% | 3830 |
|
|
2019
Q4 | $278K | Buy |
+2,081
| New | +$267K | ﹤0.01% | 3895 |
|
Other funds holding TFFP
Vanguard Group's TFFP Position: Q4 2024 in Review
Vanguard Group sold out of TFF Pharmaceuticals, Inc. Common Stock (TFFP) in Q4 2024, closing a stake of 12,136 shares — an estimated $24.4K sold.
Vanguard Group first reported a position in TFFP in Q4 2019 and held it in 20 quarters. The position peaked at $9.46M in Q1 2021. 4 funds tracked by Wall St. Rank hold TFFP as of Q4 2024.
- Vanguard Group reported no remaining TFF Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Vanguard Group sold 12,136 TFF Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $24.4K.
- Vanguard Group first reported a position in TFF Pharmaceuticals, Inc. Common Stock in Q4 2019 and held it in 20 quarters.
- Vanguard Group's TFF Pharmaceuticals, Inc. Common Stock position peaked at $9.46M in Q1 2021.
- 4 funds tracked by Wall St. Rank held TFF Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on Vanguard Group's 13F filing for Q4 2024, filed 11 Feb 2025.